No Data
Henlius H drug has been approved for a new indication, achieving significant breakthroughs in the field of lung cancer treatment.
On December 3rd, Health News | Today, henlius (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody H drug Hanszhuo (generic name: SuluLi Monoclonal Antibody Injection) has officially been approved by the National Medical Products Administration. It is applicable in combination with paclitaxel and carboplatin for the first-line treatment of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer with negative epidermal growth factor receptor gene mutation and negative anaplastic lymphoma kinase. This is the fifth indication approved for H drugs in China, and after squamous non-small cell lung cancer and extensive-stage small cell lung cancer, this product has been approved for lung cancer.
Shanghai Henlius Boosts Oncology Portfolio With Drug Approval
Henlius (02696.HK): The NMPA approved the new indication for first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with Hanseyru single-chain injection in combination with chemotherapy.
GAN LU Hui December 3rd | Henlius (02696.HK) announced that recently, the National Medical Products Administration ("NMPA") has approved the company's independently developed innovative anti-PD-1 monoclonal antibody Hansify (suluyi monoclonal antibody injection) ("Hansify") in combination with pemigatinib and carboplatin for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that is unresectable and EGFR gene mutation-negative and anaplastic lymphoma kinase (ALK) gene rearrangement-negative. This approval is primarily based on a randomized,
Henlius (02696.HK) "Hansoo" non-small cell lung cancer combination therapy registration application has been approved.
Henlius (02696.HK) announced that the company's independently developed innovative anti-PD-1 monoclonal antibody "camrelizumab" (sulilumab injection) in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) has recently obtained approval for marketing registration from the National Medical Products Administration. This new indication for treatment involves the combination of camrelizumab with pemetrexed and platinum for the first-line treatment of locally advanced or metastatic non-squamous NSCLC that is unresectable and tested negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK). The research results indicate that the combination of camrelizumab...
Express News | Fosun pharma: The registration application for the pharmaceutical of the holding subsidiary Taohong Siwu Granules has been accepted.
Express News | Fosun Pharma: The new indication approval for Surulitinib injection has been granted.
No Data
